Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 10/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.38 |
| ▸ | CDK2 | P24941 | 4/20 | 0.38 |
| ▸ | CCNK | O75909 | 2/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670444 | 0.87 | CCR6 (0.42) | CCR6 | |
| SCHEMBL31155632 | 0.86 | CCR6 (0.49) | CCR6CCNA2CDK2 | |
| SCHEMBL32670637 | 0.84 | CCR6 (0.46) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL31155687 | 0.83 | CCR6 (0.49) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL32670649 | 0.82 | JAK2 (0.43) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL25079579 | 0.80 | CCR6 (0.65) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL30284828 | 0.80 | CCR6 (0.65) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL31155565 | 0.78 | CCR6 (0.53) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL25079508 | 0.76 | CCR6 (0.54) | CCR6CCNA2CDK2CCNKCDK12 | |
| SCHEMBL32670559 | 0.76 | CCR6 (0.49) | CCR6CCNA2CDK2CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | claimed |
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | CCR6 1/4885CCNA2 3190/4885CDK2 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.